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Background: The Human papillomavirus is the most common sexually transmitted virus worldwide. The objective
of this study was to estimate: 1) the prevalence and the incidence of external genital warts (eGW) in a sample of
women attending community outpatient clinics and 2) the total number of eGW cases in the Italian female population
aged 15–64 years.
Methods: A prospective study was performed for a 12-month period between 2009 and 2010, among a sample of
women attending community gynecological outpatient clinics located throughout Italy. Demographic data, for every
woman aged 15–64 years, were collected. For women diagnosed with eGW, behavioral and clinical data were recorded.
Prevalence of eGW was calculated as the proportion between the number of women with eGW and that of women
visiting any of the participating gynecologists; incidence of eGW was calculated as the proportion between the number
of women with a new diagnosis of eGW and that of women visiting any of the participating gynecologists. Standardized
prevalence by age was used to estimate the number of eGW cases occurring in the Italian female population
aged 15–64 years.
Results: In 2009–2010, 44 community gynecologists were included in the network. In one-year period, 16,410
women visited any of the participating gynecologists; 63 women were diagnosed with eGW, corresponding to a
prevalence of 3.8 cases per 1,000 women per year (95%CI: 2.9-4.9). The incidence of eGW was 3.0 cases per 1,000
women per year (95%CI: 2.2-3.9). Women aged 15–24 years showed both the highest prevalence and incidence.
Prevalence and incidence significantly decreased by increasing age group (p <0.001), and were higher in Southern Italy
compared to Central-Northern Italy. The estimated number of women with eGW among women aged 15–64 years in
Italy, in 2010, was approximately 69,000.
Conclusions: These data show a high prevalence and incidence of eGW among young women in Italy, stress the
effectiveness of community clinical networks in investigating STI epidemiology among women from the general
population, confirm the relevance of HPV vaccination programs among adolescents, and underscore the need of
promoting safe sex, implementing early diagnosis, treatment and prevention of genital warts.
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The Human papillomavirus (HPV) is the most common
sexually transmitted virus worldwide. Among the more
than 200 different types of HPV identified so far, more
than 40 types are responsible of infections in the genital
area, causing both benign and malignant lesions [1–3].
The most common benign genital HPV infection are
genital warts, caused in about 90% of the cases by HPV
type 6 and 11 [4, 5]. Genital warts affect both males and
females; in Europe, there is an approximate burden of
500,000 cases divided almost equally between both
sexes, although slightly higher in men according to latest
data [6].
In Europe, genital warts are subject to mandatory noti-
fication only in the United Kingdom [7]. In other coun-
tries, the information on the spread of this disease is
derived from epidemiological studies, sales of medicines
specifically used for the treatment of genital warts, or
surveillance of sexually transmitted infections (STI) [6].
In Italy, women with external genital warts (eGW) are
usually diagnosed and treated in gynecological services
and sexually transmitted infection (STI) clinics. The sen-
tinel STI surveillance system based on STI clinics and
two epidemiological studies provided data on eGW in
Italy so far [8–10]. However, information obtained from
the sentinel STI surveillance system, although covering
24 years of data collection and being essential for moni-
toring trends in time, is not suitable for estimating
prevalence and incidence of single STIs in that denomi-
nators for calculating these measures are not available.
Moreover, STI clinics collect data on symptomatic
patients who are not representative of the population at
large [8]. In Italy, about 66% of women between 18 and
55 years of age undergo every year a gynecological visit
in a public and/or private gynecological setting [11].
The launch of the HPV vaccination campaign in Italy
in 2008 emphasized the debate about the cost/benefit of
HPV vaccination at National level and underscored the
lack of prevalence/incidence data on genital warts that
would be valuable as first-line efficacy indicators of the
vaccination campaign.
Taking into account this background, the Istituto
Superiore di Sanità (ISS) and the Italian Society of
Gynecology and Obstetrics (SIGO) decided in 2009 to
conduct a prospective study to estimate the prevalence
and the incidence of eGW in a sample of women attend-
ing community gynecological outpatient clinics and the
total number of women with eGW among women aged
15–64 years in Italy.
Methods
Study design and sampling method
A prospective study was performed for a 12-month
period between November 2009 and December 2010, ina sample of women attending community gynecological
outpatient clinics located throughout Italy (i.e. North,
Center, and South).
The sample selection was based on a two sampling stage
strategy: first, the selection of community gynecologists
and second, the number of women visited in one year by
each community gynecologist.
The network of community gynecologists
SIGO together with the support of the Italian Associ-
ation of Territorial Gynecologists (AGITE) in the first
phase identified 30 gynecologists to act as regional coor-
dinators, including at least one coordinator from each of
the 20 Italian regions. The study coordinators trained
the regional coordinators on the study methods and data
collection procedures.
In the second phase, a list of 485 community gynecol-
ogists was obtained from the 30 lists provided by the
regional coordinators. From this list, 320 community gy-
necologists were randomly selected and invited to par-
ticipate in the study. Of these, 44 accepted to participate
in the study. The regional coordinators trained the 44
community gynecologists who were residing in 13 of the
20 Italian regions.
As previously described [12], to be part of the net-
work, the community gynecologists needed to comply
with the following requirements:
 to dedicate part of their professional practice to
first-level consultations (they see new patients and
do the first diagnosis of the disease, they are the first
doctors/physician the patients seeks for help) or
referral consultations (patients are referred from
other specialists for diagnosis confirmation and
treatment), in either private or public practice;
 to possess a personal computer with internet
connection;
 to have at least 200 women visiting the clinic in one
year;
 to participate without any economic benefit.
Sample size calculation
Standard statistical methods used for sample size esti-
mate and analysis do not include the between-clusters
component of variability in the outcome and conse-
quently cannot be applied in cluster-based studies be-
cause they would provide sample sizes that are too small
[13]. In fact, in this case the variability of the studied
phenomenon depends on two components: the variabil-
ity within the cluster (i.e. difference in the frequency of
eGW diagnosis between women visited by the same
community gynecologist) and the variability between
clusters (i.e. differences between women visiting differ-
ent community gynecologists). The within-cluster and
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bined in a single statistical measure of between-clusters
heterogeneity (or within-cluster homogeneity), namely
the Intraclass correlation coefficient (ICC).
As previously described [12], to calculate the sample
size, the following parameters were taken into account:
 the average number of women visiting any
community gynecologist in one year;
 the expected incidence of eGW;
 the ICC.
Particularly, we assumed that the incidence of eGW in
Italy was expected between 1 and 5 per 1,000 [9]. No esti-
mate of the expected ICC in studies performed among
Italian gynecologists was available; therefore, we used sev-
eral estimates of ICC obtained from 16 datasets covering a
range of diseases for health binary outcomes [9, 14].
Finally, we performed a simulation varying the median
number of women visiting the same community
gynecologist, the expected ICC, and the width of the 95%
confidence interval (95%CI) around the expected inci-
dence of eGW. We observed that the number of commu-
nity gynecologists to be included and, consequently, the
number of women included increased with increasing ICC
(independently from the median number of women visited
per community gynecologist), and conversely decreased
with increasing 95%CI width (regardless of the ICC).
Inclusion and exclusion criteria
Women meeting the following inclusion criteria were in-
cluded [12]:
 age from 15 to 64 years;
 permanent residence in Italy (regardless of
nationality);
 visited the gynecologist at least once in a one-year
period.
 The exclusion criteria were:
 not having a permanent residence in Italy.
Definition of eGW
According to Cartier’s definition [15], eGW were defined
as flesh-colored, exophytic lesions (small bumps, flat, ver-
rucous, peduncolated, raised papules or dome-shaped le-
sions on keratinized skin) on the external genitalia,
including vulva, perineum, and perianal skin. The diagno-
sis of eGW was based on visual inspection. In order to
standardize inter-observer variation in the diagnosis of
eGW and HPV-related lesions a two-day special training
course was held.
Newly diagnosed cases of eGW included women diag-
nosed with eGW who reported never having had eGW
before.Early recurrent cases of eGW (recent relapse) included
women who reported episodes of eGW in the previous
12 months.
Late recurrent cases of eGW (late relapse) included
women who reported prior episodes of eGW but did not
suffer from any recurrence in the previous 12 months.
Data collected
Participating gynecologists reported essential individual
socio-demographic data (i.e. age, nationality, and ethni-
city) and medical history (i.e. self-reported anti-HPV
vaccination status; vaccination with bivalent or quadriva-
lent vaccine; number of pregnancies) for every woman
aged 15–64 visiting the gynecologist for any reason.
For women diagnosed with eGW the following additional
information was recorded: level of education, self-reported
behavioral data (age at first sexual intercourse, previous STI
lifetime, concurrent diseases, use of contraceptives in the
previous 12 months, number of partners in the previous
12 months), clinical data (current genitourinary symptoms
such as itching, vaginal discharge, dispareunia), written re-
sult of HIV test, reason of the consultation, type of medical
or surgical treatment of eGW and outcome of the
treatment.
Data input
The collection and management of data were made elec-
tronically through the SIGO website. Each community
gynecologist accessed the dedicated area containing data
collection forms. Data collection forms filled by every
community gynecologist were conveyed at the Contract
Research Organization (CRO) data center where data
management and analyses were performed. A tailored
data collection software performed consistency and
completeness checks on the data. The CRO performed
periodical controls on the congruency and completeness
of data entered by gynecologists.
Measures of frequency
Prevalence of eGW was calculated as the proportion be-
tween the number of women with eGW and that of
women visiting any of the participating gynecologists for
any reason in 2009–2010. Incidence of eGW was calcu-
lated as the proportion between the number of women
with a new diagnosis of eGW and that of women visiting
any of the participating gynecologists for any reason in
2009–2010.
Ninety five percent confidence intervals (95%CI) were
calculated using binomial distribution. Prevalence and
incidence were also analyzed stratifying by age group
(15–24, 25–34, 35–44, 45–64 years) and geographical
area of residence (Northern, Central, Southern Italy).
Comparisons between age groups or geographical areas
were performed using the chi-square test. Age-specific
Table 1 Socio-demographic and behavioral characteristics of 63
women with eGW




Primary school 12 19.1
Middle school 9 14.3
High school 25 39.7






Number of sexual partners in previous 12 months
0 26 41.3
1 30 47.6






Contraceptive use in previous 12 months
None
Condom 16 25.4
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incidence using as reference Italian [16] and European
standard population [17] aged 15–64 years. Age-specific
rates were used also to estimate the number of eGW cases
in the Italian female population aged 15–64 years multi-
plying the estimated prevalence by the underlying female
population. For the analysis of data, SaS.8.2 was used.
Results
In one-year period, 16,410 women, who represented 0.1%
of the total female Italian population aged 15–64 years,
visited any of the 44 community gynecologists included in
the network. Their median age was 37 years (inter quartile
range 29–47 years); 10.5% were pregnant; 12.5% were mi-
grants: of these, 56.0% were Caucasians, 17.0% Hispanic,
15.0% Asian, 11.0% African and 1.0% of other ethnicities.
Fifty women had been vaccinated for HPV; of these,
30 with the bivalent vaccine, 9 with the quadrivalent vac-
cine, and the type of vaccine was not reported for 11
women.
There were 63 women diagnosed with eGW. Socio-
demographic and behavioral characteristics of these
women are shown in Table 1. The median age at first
sexual intercourse was 17 years (inter quartile range:
15–20 years). Ten women (16.0%) reported having had
previous bacterial genital infections without specifying
the etiological agent; one woman reported having had
genital herpes, and one Chlamydia trachomatis
infection.
Moreover, 13.0% of women with eGW reported having
been tested for HIV at least once in a lifetime; none of
them was HIV positive. No woman with eGW had been
HPV-vaccinated.
Among women with eGW, the most frequent reasons
for consultation were as follows: presence of genital warts
(36.0%), check-up not related to eGW (35.0%; includes op-
portunistic cytology screening, annual check-up, post-
treatment follow-up, family planning), self-reported genital
symptoms (11.0%), pregnancy (10.0%), menopause (5.0%),
and use of oral contraceptives (5.0%) (these categories
were not mutually exclusive).
The crude prevalence of eGW was 3.8 cases per 1,000
women per year (95%CI: 2.9-4.9) (Table 2).
The highest prevalence of eGW was observed among
25–34 year-old women living in the South. Prevalence
decreased by increasing age group: this decrease was sig-
nificant even though 95%CI overlapped (p <0.001) [18]
(Table 2). When combining data of women living in the
North with those of women living in the Center (to
reach statistical significance), the prevalence of eGW
was significantly higher among women living in the
South (5.4‰ vs. 2.5‰, p = 0.003). The prevalence of
eGW among Italian and migrant women was not signifi-
cantly different (3.9‰ vs. 3.4‰, p = 0.733).Among the 63 women diagnosed with eGW, 49 were
new diagnoses corresponding to a crude incidence of 3.0
cases per 1,000 women per year (95%CI: 2.2-3.9)
(Table 3). Eight women had a recurrent eGW; of these, 4
had a late relapse and 4 had a recent relapse (corre-
sponding in both cases to an incidence of 0.2 cases per
1,000 women per year, 95%CI: 0.1-0.6). For 6 women
this clinical information was not reported.
The crude incidence of eGW significantly decreased
by increasing age group (p <0.001). The highest inci-
dence was observed among 25–34 year-old women liv-
ing in the South and 45–64 year-old women living in the
North. The incidence of eGW was higher among women
living in Southern Italy compared to those living in
Central-Northern Italy (3.9‰ vs 2.2‰, p = 0.036). The
incidence of eGW among Italian and migrant women
was not significantly different (3.4‰ vs 2.9‰, p = 0.710).











Prevalence (‰) (95% CI)
Total North Center South
15–24 18 2,491 7.2 (4.3-11.4) 8.3 (4.2-14.9) 0.0 (0–38.8) 6.5(1.6-13.9)
25–34 27 4,331 6.2 (4.1-9.1) 2.6 (1.0-5.7) 3.8 (0.1-21.1) 11.3 (6.9-17.5)
35–44 11 4,482 2.5 (1.2-4.4) 0.8 (0.1-3.0) 0.0 (0–15.8) 8.3 (4.2-14.9)
45–64 7 5,106 1.4 (0.6-2.8) 8.3 (4.2-14.9) 0.0 (0–13.9) 4.9 (2.3-9.4)
Total 63 16,410 3.8 (2.9-4.9) 2.6 (1.6-4.0) 1.2 (0.0-6.5) 5.4 (3.9-7.3)
p < 0.001 by age group; p = 0.003 North + Center vs. South
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using Italian female population as reference were 3.4 (95%
CI: 2.6-4.3) and 2.7 (95% CI: 1.9-3.4) cases per 1,000 women
aged 15–64 years, respectively. Using the European female
standard population as reference, these measures were 3.6
(95% CI: 2.7-4.5) and 2.8 (95% CI: 2.0-3.6), respectively.
Using the age-specific rates of the Italian female popula-
tion, we estimated that there were about 69,000 women
with eGW aged 15–64 years in Italy, in 2010.
Discussion
This prospective study estimated the prevalence and the
incidence of eGW in a sample of women attending com-
munity gynecology outpatient clinics in Italy.
These data are similar to those reported in a retro-
spective Italian study conducted among community gy-
necologists [9].
The prevalence of eGW estimated in the present study
(3.8 cases per 1,000) is slightly higher compared to that re-
ported in studies conducted in other European countries
in various clinical settings. In England, the prevalence of
eGW was 2.3 cases per 1,000 in a sample of women at-
tending genitourinary medicine clinics [13]. In France, it
was 2.3 cases per 1,000 in a sample of women attending
French public gynecologists [14]. In Spain, it was 1.6 cases
per 1,000 women [19] and in Germany 1.5 cases per 1,000
women [20] attending various medical specialists. In
Canada, it was 1.4 per 1,000 women based on data col-
lected by STI clinics, pharmacists, physicians billing data-













15–24 15 2,491 6.0 (4.3-11.4)
25–34 21 4,331 4.8 (4.1-9.1)
35–44 8 4,482 1.8 (1.2-4.4)
45–64 5 5,106 1.0 (0.6-2.8)
Total 49 16,410 3.0 (2.2-3.9)
p < 0.001 by age group; p = 0.036 North + Center vs. Souththe present study was higher also when compared to that
emerged in studies based on women attending general
practitioners (GP), which ranged between 0.51 and 0.59
cases per 1,000 women [10, 13, 22]. At least in the Italian
context, the network of community gynecologists is likely
to be more accurate in estimating the frequency of eGW
among women than the GP network. The reason being
that in Italy women with eGW primarily seek treatment
with a gynecologist rather than a GP [10], similarly to
what reported in England where about 70% of patients
with eGW were seen only in genitourinary medicine
clinics [13].
Conversely, the eGW prevalence estimated in this study
was much lower than that reported in a retrospective
study based on a self-administered questionnaire, con-
ducted in 70,000 women of four northern European coun-
tries (Norway, Sweden, Denmark and Iceland) which
reported a prevalence of 13 cases per 1,000 women [23].
Indeed, retrospective studies based on self-administered
questionnaire may overestimate the frequency of GW due
to a methodological bias, in that women with a history of
GW would be more prone to answer to the questionnaire.
The incidence of eGW observed in this study is similar
to that reported in other studies conducted in France
[14] and the UK [22], but higher compared to that re-
ported in other European countries, such as Spain [19]
and Germany [20].
Compared to estimates reported in a systematic review
[24], our prevalence and incidence rates are higher than
those reported in other countries. These diversities can,000)
) (95% CI)
North Central South
6.8 (3.1-13.0) 0.0 (0–38.8) 5.6 (2.0-12.1)
2.1 (0.7-5.1) 3.8 (0.1-21.1) 8.5 (4.8-14.0)
0.8 (0.1-3.0) 0.0 (0–15.8) 3.3 (1.2-7.1)
8.3 (4.2-14.9) 0.0 (0–13.9) 1.3 (0.3-3.8)
2.3 (1.3-3.6) 1.2 (0.0-6.5) 3.9 (2.7-5.6)
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age range of the study population (15–64 years in our
sample vs. larger age ranges in other studies), a different
background of the study population (women visiting a
community gynecologist in our study vs. general popula-
tion or privately-insured women in other studies), or a
different recruitment setting (community gynecologists
in our study vs. cytology screening services or GP in
other studies).
We observed the highest prevalence and incidence of
eGW was observed among 15–24 year-old women com-
pared to women older than 25 years of age, similarly to
what reported in other studies [14, 20–22, 24]. This finding
has been associated with higher levels of sexual activity with
multiple partners and low viral immunity in this age group
[2]. Previous studies conducted in Italy have shown the de-
terminant role of multiple sex partners in the prevalence of
genital HPV infection among young women [25, 26], thus
underscoring the main relevance of HPV vaccination
among adolescent females. Interestingly, our results show a
second peak in prevalence and incidence among women
aged 45–64 years living in the North; this U-shaped curve
has been reported in Southern Europe and may be related
to immuno-senescence, perimenopausal hormonal changes,
changes in male/female sexual behavior, cohort effects, or
higher rates of HPV persistence at older ages [27].
Compared to the general female Italian population
[16], our sample was younger (age group 25–34 years:
26.4% vs 19.2%), with a higher proportion of migrant
(12.5% vs 8.5%) and pregnant women (10.5% vs 1.6%).
Age-specific standardization was applied to adjust preva-
lence and incidence rates for differences in age distribu-
tion. The higher proportion of migrant or pregnant
women in our study sample may have had an impact on
the observed prevalence in that both populations have
been reported to have a higher probability of HPV
infection compared to Italian or non-pregnant women
[28, 29]. Moreover, previous studies have evidenced a
higher HPV prevalence among migrant women in
Southern Italy [29, 30], which can explain the higher
prevalence and incidence of eGW found among women
living in the South.
In Italy, the national HPV vaccination campaign
started in 2008 and targeted 12 years-old girls [31]. Our
study was conducted in the two years following the im-
plementation of the HPV vaccination program and in-
cluded women aged ≥15 years which did not allow
detecting any impact of the vaccination campaign on
study participants. Nevertheless, our results provide es-
sential epidemiological data that can be used as baseline
for future studies aimed at evaluating the effectiveness
of the Italian HPV vaccination campaign. Our study
sample included a number of HPV-vaccinated women
and none of them was diagnosed with eGW: thesewomen were not comprised in the vaccination campaign
but rather purchased the vaccine on their own.
Our estimated number of about 69,000 women with
eGW aged 15–64 years in Italy in 2010, would imply
that our sample is representative of all Italian women
and that all women visit a gynecologist routinely. How-
ever, we know that around 66% of Italian women aged
18–55 years visit a gynecologist annually [11]. Therefore,
assuming that women who do not visit a gynecologist
annually be free from eGW, then an adjusted estimate of
the total number of women aged 15–64 with eGW
would be approximately 45,500 (i.e., 69,000 x 0.66). This
figure should be considered as a minimum estimate,
which implies that among the 34% of women who do
not visit a gynecologist none is suffering from eGW.
Some limitations of this study should be addressed. The
main limitation was the small number of community gyne-
cologists who accepted to participate, which was probably
attributable to the free and unpaid participation in the net-
work. Another limitation was the lack of geographic repre-
sentativeness of the participating gynecologists that resided
in only 13 of the 20 Italian regions. Finally, our network of
community gynecologists, though composed of generalist
gynecologists, may have concentrated a population at
higher risk of eGW in the study period due to the estab-
lished general experience of these gynecologists.
Our surveillance network of community gynecologists
shows several strengths. First, a low cost as the participa-
tion of gynecologists in the network was voluntary with-
out any economic compensation. Second, women enrolled
in the study were not selected by the presence of specific
symptoms and included both symptomatic and asymp-
tomatic patients attending for a routine visit or annual
check-up, unlike STI specialists that see mainly symptom-
atic patients. Third, participating gynecologists were ad-
equately trained on genital warts and could provide
reliable diagnosis and follow-up of patients. Fourth, com-
munity gynecologists collected essential data on the num-
ber and the characteristics of visited women, providing
the denominator required for estimating the burden of
eGW in terms of frequency, incidence and prevalence.
Fifth, the user-friendly data-collection software facilitated
input and linkability of patient’s longitudinal data, allow-
ing also for real-time transmission of data. Sixth, all infor-
mation was centralized thus optimizing data management
and analysis.
Conclusions
This prospective study was based on an innovative sur-
veillance network composed of a sample of community
gynecologists located in 13 Italian regions.
These data stress the effectiveness of community clin-
ical networks in investigating STI epidemiology among
women from the general population, promoting safe sex
Suligoi et al. BMC Infectious Diseases  (2017) 17:126 Page 7 of 8and implementing early diagnosis, treatment and preven-
tion. Moreover, this study provides evidence of the para-
mount importance of HPV vaccination among adolescents,
which has already proved to reduce dramatically the inci-
dence of GW in several countries [32]. Indeed, although
GW represent a benign condition, treatment costs and im-
pact on psycho-sexual life enforce the need of preventing
the occurrence of these lesions.
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